External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
Background A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2020-06, Vol.181 (2), p.339-345 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 345 |
---|---|
container_issue | 2 |
container_start_page | 339 |
container_title | Breast cancer research and treatment |
container_volume | 181 |
creator | Piñero-Madrona, Antonio Ripoll-Orts, Francisco Sánchez-Méndez, José Ignacio Chaves-Benito, Asunción Gómez-de la Bárcena, Maximiliano Rodrigo Calatrava-Fons, Ana Menjón-Beltrán, Salomón Peg-Cámara, Vicente |
description | Background
A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.
Methods
We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP).
Results
The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test
p
|
doi_str_mv | 10.1007/s10549-020-05623-4 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7188708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A622303449</galeid><sourcerecordid>A622303449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-1d525c3b1a68cbccdab65210ee6fd80c8008cf606f93132fe3fc0b0497c051e73</originalsourceid><addsrcrecordid>eNp9kk9rFTEUxQdR7LP6BVxIQBA3U2-SSTKzEUqpf6DgRtchk8m8l5JJxiRTfPjlzfhq2yciWQRyfvdc7s2pqpcYzjCAeJcwsKargUANjBNaN4-qDWaC1oJg8bjaAOai5i3wk-pZStcA0AnonlYnlBBGedtsqp-XP7KJXjl0o5wdVLbBozAiheYYtj6kbDWawmAc6lUyAypyDrnweZlCRC6oYeWT8dn6Qrn9NO-QLxVoLLpR0e1RH41KGWnltYloLl0Knp5XT0blknlxe59W3z5cfr34VF99-fj54vyq1kyQXOOBEaZpjxVvda_1oHrOCAZj-Di0oFuAVo8c-NhRTMlo6Kihh6YTGhg2gp5W7w--89JPZtCld1ROztFOKu5lUFYeK97u5DbcSIHbVkBbDN7eGsTwfTEpy8kmbZxT3oQlSUJbQVgHuCno67_Q67Cs-12pjjWMs47dU1vljLR-DKWvXk3lOSeEAm2arlBn_6DKGcxkdfBmtOX9qODNg4KdUS7vUnDL-qnpGCQHUMeQUjTj3TIwyDVb8pAtWbIlf2dLrqO9erjGu5I_YSoAPQCpSH5r4v3s_7H9BX3K2e4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2395456595</pqid></control><display><type>article</type><title>External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients</title><source>Springer Nature - Complete Springer Journals</source><creator>Piñero-Madrona, Antonio ; Ripoll-Orts, Francisco ; Sánchez-Méndez, José Ignacio ; Chaves-Benito, Asunción ; Gómez-de la Bárcena, Maximiliano Rodrigo ; Calatrava-Fons, Ana ; Menjón-Beltrán, Salomón ; Peg-Cámara, Vicente</creator><creatorcontrib>Piñero-Madrona, Antonio ; Ripoll-Orts, Francisco ; Sánchez-Méndez, José Ignacio ; Chaves-Benito, Asunción ; Gómez-de la Bárcena, Maximiliano Rodrigo ; Calatrava-Fons, Ana ; Menjón-Beltrán, Salomón ; Peg-Cámara, Vicente</creatorcontrib><description>Background
A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.
Methods
We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP).
Results
The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test
p
< 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set.
Conclusions
The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-020-05623-4</identifier><identifier>PMID: 32253684</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Analysis ; Biopsy ; Breast cancer ; Cancer patients ; Cancer research ; Care and treatment ; Clinical Trial ; Lymph nodes ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Oncology ; Patients ; Predictions ; Surgery</subject><ispartof>Breast cancer research and treatment, 2020-06, Vol.181 (2), p.339-345</ispartof><rights>The Author(s) 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-1d525c3b1a68cbccdab65210ee6fd80c8008cf606f93132fe3fc0b0497c051e73</citedby><cites>FETCH-LOGICAL-c572t-1d525c3b1a68cbccdab65210ee6fd80c8008cf606f93132fe3fc0b0497c051e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-020-05623-4$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-020-05623-4$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32253684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piñero-Madrona, Antonio</creatorcontrib><creatorcontrib>Ripoll-Orts, Francisco</creatorcontrib><creatorcontrib>Sánchez-Méndez, José Ignacio</creatorcontrib><creatorcontrib>Chaves-Benito, Asunción</creatorcontrib><creatorcontrib>Gómez-de la Bárcena, Maximiliano Rodrigo</creatorcontrib><creatorcontrib>Calatrava-Fons, Ana</creatorcontrib><creatorcontrib>Menjón-Beltrán, Salomón</creatorcontrib><creatorcontrib>Peg-Cámara, Vicente</creatorcontrib><title>External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Background
A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.
Methods
We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP).
Results
The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test
p
< 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set.
Conclusions
The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.</description><subject>Analysis</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Care and treatment</subject><subject>Clinical Trial</subject><subject>Lymph nodes</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Oncology</subject><subject>Patients</subject><subject>Predictions</subject><subject>Surgery</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kk9rFTEUxQdR7LP6BVxIQBA3U2-SSTKzEUqpf6DgRtchk8m8l5JJxiRTfPjlzfhq2yciWQRyfvdc7s2pqpcYzjCAeJcwsKargUANjBNaN4-qDWaC1oJg8bjaAOai5i3wk-pZStcA0AnonlYnlBBGedtsqp-XP7KJXjl0o5wdVLbBozAiheYYtj6kbDWawmAc6lUyAypyDrnweZlCRC6oYeWT8dn6Qrn9NO-QLxVoLLpR0e1RH41KGWnltYloLl0Knp5XT0blknlxe59W3z5cfr34VF99-fj54vyq1kyQXOOBEaZpjxVvda_1oHrOCAZj-Di0oFuAVo8c-NhRTMlo6Kihh6YTGhg2gp5W7w--89JPZtCld1ROztFOKu5lUFYeK97u5DbcSIHbVkBbDN7eGsTwfTEpy8kmbZxT3oQlSUJbQVgHuCno67_Q67Cs-12pjjWMs47dU1vljLR-DKWvXk3lOSeEAm2arlBn_6DKGcxkdfBmtOX9qODNg4KdUS7vUnDL-qnpGCQHUMeQUjTj3TIwyDVb8pAtWbIlf2dLrqO9erjGu5I_YSoAPQCpSH5r4v3s_7H9BX3K2e4</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Piñero-Madrona, Antonio</creator><creator>Ripoll-Orts, Francisco</creator><creator>Sánchez-Méndez, José Ignacio</creator><creator>Chaves-Benito, Asunción</creator><creator>Gómez-de la Bárcena, Maximiliano Rodrigo</creator><creator>Calatrava-Fons, Ana</creator><creator>Menjón-Beltrán, Salomón</creator><creator>Peg-Cámara, Vicente</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200601</creationdate><title>External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients</title><author>Piñero-Madrona, Antonio ; Ripoll-Orts, Francisco ; Sánchez-Méndez, José Ignacio ; Chaves-Benito, Asunción ; Gómez-de la Bárcena, Maximiliano Rodrigo ; Calatrava-Fons, Ana ; Menjón-Beltrán, Salomón ; Peg-Cámara, Vicente</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-1d525c3b1a68cbccdab65210ee6fd80c8008cf606f93132fe3fc0b0497c051e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Care and treatment</topic><topic>Clinical Trial</topic><topic>Lymph nodes</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Oncology</topic><topic>Patients</topic><topic>Predictions</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piñero-Madrona, Antonio</creatorcontrib><creatorcontrib>Ripoll-Orts, Francisco</creatorcontrib><creatorcontrib>Sánchez-Méndez, José Ignacio</creatorcontrib><creatorcontrib>Chaves-Benito, Asunción</creatorcontrib><creatorcontrib>Gómez-de la Bárcena, Maximiliano Rodrigo</creatorcontrib><creatorcontrib>Calatrava-Fons, Ana</creatorcontrib><creatorcontrib>Menjón-Beltrán, Salomón</creatorcontrib><creatorcontrib>Peg-Cámara, Vicente</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piñero-Madrona, Antonio</au><au>Ripoll-Orts, Francisco</au><au>Sánchez-Méndez, José Ignacio</au><au>Chaves-Benito, Asunción</au><au>Gómez-de la Bárcena, Maximiliano Rodrigo</au><au>Calatrava-Fons, Ana</au><au>Menjón-Beltrán, Salomón</au><au>Peg-Cámara, Vicente</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>181</volume><issue>2</issue><spage>339</spage><epage>345</epage><pages>339-345</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Background
A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.
Methods
We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP).
Results
The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test
p
< 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set.
Conclusions
The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32253684</pmid><doi>10.1007/s10549-020-05623-4</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2020-06, Vol.181 (2), p.339-345 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7188708 |
source | Springer Nature - Complete Springer Journals |
subjects | Analysis Biopsy Breast cancer Cancer patients Cancer research Care and treatment Clinical Trial Lymph nodes Medical research Medicine Medicine & Public Health Medicine, Experimental Oncology Patients Predictions Surgery |
title | External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A33%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=External%20validation%20of%20a%20prognostic%20model%20based%20on%20total%20tumor%20load%20of%20sentinel%20lymph%20node%20for%20early%20breast%20cancer%20patients&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Pi%C3%B1ero-Madrona,%20Antonio&rft.date=2020-06-01&rft.volume=181&rft.issue=2&rft.spage=339&rft.epage=345&rft.pages=339-345&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-020-05623-4&rft_dat=%3Cgale_pubme%3EA622303449%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2395456595&rft_id=info:pmid/32253684&rft_galeid=A622303449&rfr_iscdi=true |